BIVI ▲ +7.4% - BioVie Inc. $BIVI - BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID BioVie shares rose 7.4% after the company announced it has completed the treatment phase of its ADDRESS-LC trial evaluating bezisterim for neurological symptoms in long COVID patients. The completion of this trial phase represents meaningful progress in the company's clinical development program, which likely prompted the positive market reaction. The next step would typically be data analysis and potential regulatory discussions based on the trial results. 31-AUG-2026 08:01 AM ET